Ibuprofen And Famotidine Tablet
Product Images NDC 31722-315

Premature Closure of Fetal Ductus Arteriosus The use of NSAIDs, such as Ibuprofen and famoidine tablet, after 30 weeks of pregnancy, increases the risk of premature closure of the fetal ductus arteriosus. Oligohydramnios/Neonatal Renal Impairment The use of NSAIDs after 20 weeks of pregnancy has been linked to cases of fetal renal dysfunction, resulting in oligohydramnios. In some instances, it may also lead to neonatal renal impairment.*

Ibuprofen is a medication that is commonly used for pain relief and inflammation. However, there are some risks associated with its use during pregnancy. Studies have shown that the use of NSAIDs (non-steroidal anti-inflammatory drugs) like ibuprofen around 30 weeks of gestation or later can lead to the premature closure of the fetal ductus arteriosus, which is a blood vessel in the heart. Maternal use of NSAIDs around 20 weeks of gestation or later has also been associated with fetal renal dysfunction, leading to a condition called oligohydramnios, which is a low level of amniotic fluid. In some cases, this can also result in neonatal renal impairment. These adverse effects may occur after a few days to weeks of treatment, but in some cases, they can manifest as early as 48 hours after initiating NSAID use. However, it should be noted that the decrease in amniotic fluid is often temporary and reversible when the drug is stopped, although there have been cases where renal dysfunction persisted and required invasive procedures for treatment. It is important to consider the limitations of the available studies and reports, as there is a lack of control groups, limited information on dose, duration, and timing of drug exposure, as well as concomitant use of other medications. Therefore, it is not possible to establish a reliable estimate of the risk of adverse fetal and neonatal outcomes with maternal NSAID use. Moreover, most of the published safety data on neonatal outcomes only involve preterm infants, so it is uncertain how applicable these risks are to full-term infants exposed to NSAIDs through maternal use. In addition to the potential risks mentioned above, when ibuprofen or other prostaglandin synthesis inhibitors are used to delay preterm labor, there is an increased risk of other neonatal complications such as necrotizing enterocolitis and intracranial hemorrhage. Furthermore, when ibuprofen is given in late pregnancy to delay parturition, it has been associated with persistent pulmonary hypertension, renal dysfunction, and abnormal prostaglandin E levels in preterm infants. It is important for pregnant individuals to consult with their healthcare provider before using ibuprofen or any other medication to understand the potential risks and benefits and make an informed decision.*

This text mentions several health conditions and risks, including heart attack, stroke, liver problems (including liver failure), high blood pressure (which can worsen or be new), heart failure, kidney problems (including kidney failure), life-threatening allergic reactions, asthma attacks (in individuals who already have asthma), life-threatening skin reactions, and low red blood cells (anemia).*

This text appears to be a list of symptoms and potential health issues. It mentions symptoms such as nausea, increased fatigue or weakness, diarrhea, itching, yellowing of the skin or eyes, indigestion or stomach pain, flu-like symptoms, vomiting blood, presence of blood in bowel movements, black and sticky stool, unusual weight gain, skin rash or blisters with fever, and swelling of the arms, legs, hands, and feet. These symptoms could indicate various health conditions, and it is recommended to consult a healthcare professional for proper evaluation and diagnosis.*

Increased risk of heart attack or stroke, as well as bleeding, ulcers, and tears of the esophagus, stomach, and intestines may occur with the use of NSAID-containing medicines. This risk may be higher with increasing doses and longer use of these medicines. It is important to avoid taking Ibuprofen and famotidine tablet before or after a heart surgery called "coronary artery bypass graft (CABG)" and after a recent heart attack, unless specifically instructed by a healthcare provider. Factors that further increase the risk of bleeding and ulcers include a history of stomach ulcers, smoking, drinking alcohol, taking certain medications, older age, poor health, advanced liver disease, and bleeding problems.*

This text appears to be a list of medical conditions and disorders. It mentions musculoskeletal and connective tissue disorders, specifically "Atagia" and back pain. It also includes nervous system disorders such as headaches, respiratory, thoracic and mediastinal disorders like cough and pharyngolaryngeal pain, and vascular disorders like hypertension.*

Table 2 provides the incidence of adverse reactions in controlled studies for two medications: huprofen and buprofen (N=511) and famotidine tablets (N=1022). The table includes various categories of adverse reactions and their corresponding percentages. Some examples of adverse reactions reported include anemia, nausea, dyspepsia, diarrhea, constipation, abdominal pain, vomiting, stomach discomfort, edema peripheral, upper respiratory tract infection, nasopharyngitis, sinusitis, bronchitis, urinary tract infection, and influenza.*

Table 5 in Study 303 provides the overall incidence rate of patients who developed at least one gastric or upper gastrointestinal ulcer. The study evaluated the effects of Ibuprofen and Ibuprofen Pvalue® as well as famotidine tablet in treating these ulcers. The primary endpoint of the study was the incidence of gastric ulcers, and the secondary endpoint was the incidence of upper gastrointestinal ulcers. The table presents the incidence rates of these ulcers for each treatment group, expressed as a percentage. The Cochran-Mantel-Haenszel test was used for statistical analysis. The text also mentions the classification of early terminated patients and the criteria for considering them to have an ulcer.*